Qualitek Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Unaudited Financial Result (Standalone and Consolidated) of the Company for half year ended September 30, 2026 along with Limited Review Report of the Statutory Auditor

Date: November 03, 2026 The Manager - Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001 Scrip Code: 544091 | Symbol: QLL Subject: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that a meeting of the Board of Directors of Qualitek Labs Limited (“the Company”) is scheduled to be held on Friday, November 13, 2026, inter alia, to: 1. Consider, approve and take on record the Unaudited Financial Results (Standalone and Consolidated) of the Company for the half year ended September 30, 2026, along with the Limited Review Report of the Statutory Auditors thereon; 2. Consider and approve the proposal for alteration of the Memorandum of Association of the Company, subject to the approval of the members of the Company; 3. Consider and approve the convening of an Extraordinary General Meeting of the members of the Company and the Notice thereof; and 4. Transact such other business as may be deemed necessary with the permission of the Chair. Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the Trading Window for dealing in the securities of the Company has been closed from Thursday, October 1, 2026, and will remain closed until 48 hours after the declaration of the Unaudited Financial Results of the Company for the half year ended September 30, 2026. The aforesaid information shall also be made available on the Company’s website at: https://www.qualiteklab.com/compliances/ You are requested to kindly take the above information on record. Thanking you, Yours faithfully, For Qualitek Labs Limited Antaryami Nayak MD & CEO DIN: 07232463